Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kaiyuzhishen Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by researchers at Zhongda Hospital, Southeast University, for the treatment of major depressive disorder (MDD). The decoction is formulated based on TCM principles to address patterns of liver qi stagnation and spirit disturbance, which are commonly associated with mood disorders. In clinical trials, it has been evaluated in interventional parallel-group studies comparing low-dose and high-dose formulations against the selective serotonin reuptake inhibitor (SSRI) paroxetine. The primary clinical endpoints for these studies include changes in the Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale (HAMA) over a 6- to 8-week treatment period, alongside safety assessments for adverse events.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kaiyuzhishen Decoction.